Vitrolife obtains patent for Swemed Sense™ in Europe

Swemed Sense™ is a unique needle that is used for the collection of oocytes in connection with IVF. The approved patent means that Vitrolife has both design protection and product patent protection for Swemed Sense™ in strategically important European markets. A patent has also been applied for in other prioritized markets.

A recently presented study shows that Swemed Sense™ gives less pain and bleeding during the collection of oocytes, compared with a conventional needle.

Swemed Sense™ has a unique design, as advantages from both thin and thick needles are combined in one and the same needle. Swemed Sense™ is designed with a thinner front part and tip so as to minimize tissue damage, bleeding and pain. The rear part of the needle has a larger diameter, which means that the needle is stable and at the same time maintains flow and speed.

The market for needles used in the collection of oocytes for IVF is estimated to amount to approximately 40 million Euros globally.

January 14, 2011

Gothenburg

Magnus Nilsson

CEO

Related files

Queries should be addressed to:

Magnus Nilsson, CEO, phone +46 31 721 80 61

Anne-Lie Sveder, CFO, phone +46 31 721 80 13